United States Cen­ters for Dis­ease Con­trol and Pre­ven­tion (US CDC). MMWR. 14 Decem­ber 2012. 61(49):1008–11.
Avail­able at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6149a3.htm

Excerpt. Qual­ity sur­veil­lance is crit­i­cal to the con­trol and elim­i­na­tion of vaccine-preventable dis­eases (VPDs). A key strat­egy for enhanc­ing VPD sur­veil­lance, out­lined in the World Health Orga­ni­za­tion (WHO) Global Frame­work for Immu­niza­tion Mon­i­tor­ing and Sur­veil­lance (GFIMS), is to expand and link exist­ing VPD sur­veil­lance sys­tems (par­tic­u­larly those devel­oped for polio erad­i­ca­tion and measles elim­i­na­tion) to include other pri­or­ity VPDs. Since the launch of the Global Polio Erad­i­ca­tion Ini­tia­tive in 1988, the inci­dence of polio has decrease by 99% world­wide. A cor­ner­stone of this suc­cess is a sen­si­tive sur­veil­lance sys­tem based on the rapid and timely report­ing of all acute flac­cid paral­y­sis (AFP) cases in chil­dren aged <15 years, with con­fir­ma­tory diag­nos­tic test­ing per­formed by lab­o­ra­to­ries that are part of a global net­work. As coun­tries achieve polio-free sta­tus, many have expanded syn­dromic sur­veil­lance to include per­sons with rash and fever, and have built measles diag­nos­tic capac­ity in exist­ing polio ref­er­ence lab­o­ra­to­ries. Acute meningitis/encephalitis syn­drome (AMES) and acute encephali­tis syn­drome (AES) are can­di­dates for expanded sur­veil­lance because they are most often caused by VPDs of pub­lic health impor­tance for which con­fir­ma­tory lab­o­ra­tory tests exist. Vaccine-preventable cases of encephali­tis include approx­i­mately 68,000 Japan­ese encephali­tis (JE) cases, result­ing in 13,000–20,000 deaths each year in Asia. More­over, although bac­te­r­ial menin­gi­tis inci­dence in Asia is not as well-documented, pneu­mo­coc­cal and meningo­coc­cal menin­gi­tis out­breaks have been reported in Bangladesh and China, and the inci­dence of Haemophilus influen­zae type b (Hib) menin­gi­tis in chil­dren aged <5 years in India has been esti­mated to be 7.1 per 100,000 pop­u­la­tion, sim­i­lar to that in Euro­pean coun­tries before the intro­duc­tion of vac­cine. This report describes a pro­to­type for expand­ing exist­ing polio and measles sur­veil­lance net­works in Bangladesh, China, and India to include sur­veil­lance for viral and bac­te­r­ial vaccine-preventable causes of AMES and AES and presents data from 2006–2008.